Survival benefit of concurrent chemoradiotherapy for advanced ampulla of Vater cancer

Table 1 Univariate and multivariate analyses for recurrence-free survival

	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Sex (male)	1.988 (0.568-6.955)	0.282
Age	0.976 (0.939-1.014)	0.215
Size	0.816 (0.530-1.255)	0.354
T stage	1.808 (0.485-6.743)	0.378	1.952 (0.499-7.628)	0.326
LN metastasis (positive)	2.026 (0.747-5.498)	0.166	1.848 (0.522-6.541)	0.341
LVI (positive)	2.971 (1.123-7.861)	0.028a	2.002 (0.589-6.806)	0.266
PNI (positive)	1.026 (0.395-2.663)	0.958
Differentiation (poor)	1.366 (0.504-3.706)	0.540
CCRT	1.543 (0.594-4.006)	0.373
Bilirubin	0.935 (0.864-1.01)	0.089
CEA (≥ 5 ng/mL)	0.429 (0.056-3.288)	0.416
CA19.9 (≥ 39 U/L)	0.635 (0.225-1.796)	0.392
CRP (≥ 0.5 mg/mL)	1.139 (0.367-3.536)	0.822
Albumin (< 3.3 or > 5.2 mg/dL)	0.903 (0.119-6.831)	0.922
PLR	1.001 (0.997-1.005)	0.661
NLR	0.999 (0.871-1.144)	0.983

^aP < 0.05.

LN: Lymph node; LVI: Lymphovascular invasion; PNI: Perineural invasion; CCRT: Concurrent chemoradiotherapy; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CRP: C-reactive protein; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; HR: Hazard ratio; CI: Confidence interval.